Cue Biopharma Inc
CUE
Get informed when a big investor buys or sells
+ FollowMarket Cap$57.55M
Close$
$-0.76
102.8% downside
Current Fair Value
102.8% downsideOvervalued by 102.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $57.55 Million |
|---|---|
| Enterprise Value | $44.61 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.4 |
| Beta | 2.39 |
| Outstanding Shares | 4,807,494 |
Return
| Return on Equity | -90.35% |
|---|---|
| Return on Assets | -63.23% |
| Return on Invested Capital | -84.07% |
Valuation & Multiples
| P/E Ratio | -5.39 |
|---|---|
| PEG | 9.34 |
| Price to Sales | 4.49 |
| Price to Book Ratio | 6.73 |
| Enterprise Value to Revenue | 1.36 |
| Enterprise Value to EBIT | -2.26 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-3.30
Average shareholder expectationRevenue Estimate
$2.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
$-1.69
Average shareholder expectationRevenue Estimate
$3.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 12,700▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.81%▼ 1.80% |
|---|---|
| Total Invested | $4.96M▼ 25.48% |
| Investors Holding | 54▲ 6.00% |
ESG Score
No data
About Cue Biopharma Inc
CEO: Daniel Passeri